Rituximab Withdrawal: High Hepatitis B Reactivation Risk Demands Vigilance

A recent article in the EMJ (European Medical Journal) underscores a critical health concern: patients with chronic Hepatitis B Virus (HBV) infection who have undergone rituximab-based chemotherapy face a markedly higher risk of HBV reactivation once their antiviral prophylaxis is withdrawn. The study, which conducted a real-world retrospective analysis, found that most severe hepatitis flares (approximately 88%) emerge within the first year following the cessation of prophylactic nucleos(t)ide analogue (Nuc) antiviral therapy, highlighting a crucial window of vulnerability. Rituximab, a potent CD20-targeting monoclonal antibody, is widely employed in the treatment of various B-cell lymphoproliferative disorders, such as non-Hodgkin lymphoma, as well as certain autoimmune diseases. While highly effective in its therapeutic role, rituximab is recognized for its profound immunosuppressive effects, which can significantly impair immune control over latent HBV. This B-cell depletion is a primary mechanism behind the increased risk of HBV reactivation, even in individuals with previously resolved HBV infection (HBsAg-negative but anti-HBc-positive). The EMJ article details findings from a cohort study comparing outcomes after antiviral withdrawal across different patient groups. It reported a substantially higher two-year incidence of severe hepatitis flares in the rituximab group (22%) compared to non-rituximab lymphoma patients (8%). When contrasted with HBeAg-negative chronic hepatitis B controls, these rates further escalated to 32% versus 7%, respectively. This data reinforces the established understanding that rituximab significantly contributes to the risk of HBV reactivation. Studies have reported reactivation rates ranging from 2% to 35%, and even as high as 24-67% in HBsAg-positive patients without prophylaxis, with mortality rates of 5-41% if hepatic failure occurs. Several factors were identified as being linked to a higher relapse risk, including a higher baseline viral load and elevated hepatitis B surface antigen (HBsAg) levels at the end of treatment. The use of antivirals with a lower genetic barrier and specific viral rebound patterns also helped identify individuals more prone to developing severe flares. The clinical implications of these findings are substantial. Prophylactic antiviral therapy is a well-established standard of care for reducing HBV-related complications during immunosuppressive chemotherapy. However, the risk of reactivation after discontinuation of this prophylaxis remains a recognized challenge, affecting up to one-third of patients in some cohorts. The new data strongly suggest that patients exposed to rituximab may require more stringent and extended post-treatment surveillance than previously assumed. Enhanced monitoring, particularly during the first year after antiviral withdrawal, could enable earlier detection of viral rebound and help prevent progression to severe hepatitis or potentially fatal liver failure. Major medical organizations, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), provide guidelines for the management of HBV reactivation. These guidelines recommend universal HBV screening prior to any rituximab administration, as it carries one of the highest reactivation risks among immunosuppressive agents. Prophylactic antiviral therapy is mandatory for HBsAg-positive patients, regardless of their HBV DNA level, and should ideally be started 2-4 weeks before the first rituximab dose. The duration of this prophylaxis is also critical; guidelines often recommend continuing it for at least 12 months, and often 18-24 months, after the last rituximab dose, as reactivation can occur even several months or years post-treatment. For patients with resolved HBV infection (HBsAg negative, anti-HBc positive), monitoring HBV DNA levels regularly, usually every 1-3 months, is recommended, with pre-emptive antiviral treatment initiated if HBV DNA becomes detectable. For an audience in India, this news carries particular importance. India faces a significant burden of viral hepatitis, with an estimated 2-4% of its population, or roughly 29-40 million people, living with chronic Hepatitis B infection. This places India among the top 10 countries globally for HBV prevalence and related deaths. Gaps in vaccination coverage, unsafe exposures, and missed screening opportunities contribute to this high burden. Given the widespread use of rituximab in oncology and rheumatology, and the high prevalence of HBV in India, healthcare providers must be especially vigilant in adhering to screening, prophylaxis, and extended monitoring protocols. Improved awareness and rigorous implementation of these strategies are essential to mitigate the risk of severe HBV reactivation and its potentially fatal consequences in Indian patients receiving rituximab. The insights from this EMJ article reinforce the ongoing need to individualize follow-up strategies and enhance patient education regarding the importance of adherence to monitoring and prophylaxis regimens. In conclusion, the documented higher risk of HBV reactivation after rituximab withdrawal necessitates a re-evaluation of post-prophylaxis monitoring strategies. Clinicians treating patients with chronic or resolved HBV infection using rituximab must ensure comprehensive screening, initiate timely and appropriate antiviral prophylaxis, and maintain extended, vigilant surveillance after prophylaxis cessation to minimize the risk of severe and potentially life-threatening hepatitis flares. This is particularly crucial in regions like India, where HBV endemicity adds another layer of complexity to patient management.

Frequently Asked Questions

Read Full Story on Quick Digest